Subjecting meta-analyses to closer scrutiny: Little support for differential efficacy among second-generation antipsychotics at equivalent doses [1]

Archives of General Psychiatry

Volumn 63, Issue 8, 2006, Pages 935-937

  Tandon, Rajiv ^a   Nasrallah, Henry A ^b  

^a Florida Department of Children and Families   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; LETTER; LOW DRUG DOSE; META ANALYSIS; METHODOLOGY; PRESCRIPTION; SCHIZOPHRENIA; SYSTEMATIC REVIEW; UNITED STATES;

ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTERNET; META-ANALYSIS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 33746870356     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.8.935     Document Type: Letter

References (21)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
2. Nasrallah HA, Smeltzer DJ. Contemporary Diagnosis and Management of the Patient With Schizophrenia. Philadelphia, Pa: Handbooks in Healthcare; 2002:170-212.
3. Arvanitis LA, Miller G. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42:233-246.
4. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG; Seroquel Study Group. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;54:549-557.
5. Emsley RA, Raniwalla J, Bailey PJ, Jones AM; PRIZE Study Group. A comparison of the effects of quetiapine ("Seroquel") and haloperidol in schizo phrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol. 2000;15:121-131.
6. Kane J, Khanna S, Rajadhyaksha S, Giller E. Ziprasidone versus chlorpromazine in treatment-refractory schizophrenia. Paper presented at: 41st American College of Neuropsychopharmacology Annual Meeting; December 9, 2002; San Juan, PR.
7. Cook DJ, Guyatt GH, Ryan G, Clifton J, Buckingham L, Willan A, McIlroy W, Oxman AD. Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA. 1993;269:2749-2753.
8. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res. 2005;79:145-155.
9. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001;158:518-526.
10. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185-194.
11. Tandon R. Comparing antipsychotic efficacy. Am J Psychiatry. In press.
12. Lieberman JA, Stroup ST, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
13. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64 (suppl 12):2-97, quiz 98-100.
14. Constantine RJ, Richard SM, Surles RC, Medvedeff D, Dewan NA, Mann L, Williamson JM, Tandon R. Optimizing pharmacotherapy of schizophrenia: tools for the psychiatrist. Current Psychosis and Therapeutics Reports. 2006;4:5-11.
15. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192-208.
16. Tandon R. Comparative effectiveness of antipsychotics in the treatment of schizophrenia: what does CATIE tell us? Int Drug Ther Newsl. 2006;41:51-58.
17. Kane JM. Commentary on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) J Clin Psychiatry. 2006;67:831-832.
18. Nasrallah HA. CATIE's surprises. Current Psychiatry. 2006;5:49-65.
19. Lieberman J, McEvoy JP, Perkins D, Hamer RH. Comparison of atypicals in first-episode psychosis: a randomized 52-week comparison of olanzapine, quetiapine, and risperidone. Eur Neuropsychopharmacol. 2005;15(suppl 3):S525.
20. Tamminga CA. Practical treatment information for schizophrenia. Am J Psychiatry. 2006;163:563-565.
21. Tandon R. Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q. 2002;73:297-311.